247 related articles for article (PubMed ID: 19446318)
21. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
22. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
[TBL] [Abstract][Full Text] [Related]
23. Paclitaxel/carboplatin as first-line chemotherapy in advanced ovarian cancer: efficacy and adverse effects with special consideration of peripheral neurotoxicity.
Mayerhofer K; Bodner-Adler B; Bodner K; Leodolter S; Kainz C
Anticancer Res; 2000; 20(5C):4047-50. PubMed ID: 11268499
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
Vasey PA; Atkinson R; Coleman R; Crawford M; Cruickshank M; Eggleton P; Fleming D; Graham J; Parkin D; Paul J; Reed NS; Kaye SB
Br J Cancer; 2001 Jan; 84(2):170-8. PubMed ID: 11161372
[TBL] [Abstract][Full Text] [Related]
25. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant chemotherapy for advanced ovarian cancer.
Schwartz PE; Chambers JT; Makuch R
Gynecol Oncol; 1994 Apr; 53(1):33-7. PubMed ID: 8175019
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
28. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Bolis G; Scarfone G; Tateo S; Mangili G; Villa A; Parazzini F
Gynecol Oncol; 2001 Jan; 80(1):13-5. PubMed ID: 11136562
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of topotecan, carboplatin, and paclitaxel as front-line therapy in suboptimal advanced epithelial ovarian cancer.
Bolis G; Scarfone G; Villa A; Parazzini F
Gynecol Oncol; 2001 May; 81(2):331-3. PubMed ID: 11330974
[No Abstract] [Full Text] [Related]
30. Chemotherapy for malignant mixed Müllerian tumors of the ovary.
Sit AS; Price FV; Kelley JL; Comerci JT; Kunschner AJ; Kanbour-Shakir A; Edwards RP
Gynecol Oncol; 2000 Nov; 79(2):196-200. PubMed ID: 11063643
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of intraperitoneal carboplatin as adjuvant treatment in early-stage ovarian cancer patients.
Malmström H; Simonsen E; Westberg R
Gynecol Oncol; 1994 Jan; 52(1):20-5. PubMed ID: 8307496
[TBL] [Abstract][Full Text] [Related]
32. [Maintenance of the dose-intensity of chemotherapy combining carboplatin, cyclophosphamide, etoposide in women with ovarian cancer aged 70 and over].
Delva R; Mege M; Gamelin E; Maillart P; Lortholary A; Guérin O; Pein F; Larra F
Bull Cancer; 1996 Jan; 83(1):63-69. PubMed ID: 8672858
[TBL] [Abstract][Full Text] [Related]
33. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
[TBL] [Abstract][Full Text] [Related]
34. [Patient compliance and the quality of life are well maintained in weekly paclitaxel and carboplatin therapy for advanced gynecologic cancers in Japanese women].
Kurihara M; Sakamoto H; Ohta Y; Takami T; Takami M; Nakayama Y; Murata H; Ohtani K; Masaoka N; Yamamoto T; Satoh K
Gan To Kagaku Ryoho; 2001 Jan; 28(1):55-61. PubMed ID: 11201381
[TBL] [Abstract][Full Text] [Related]
35. [Dose finding study of paclitaxel and carboplatin for ovarian cancer (JKTB)].
Yasuda M; Kimura E; Ochiai K; Tada S; Udagawa Y; Aoki D; Nozawa S; Kikuchi Y; Kita T; Nishida M; Tsunoda H
Gan To Kagaku Ryoho; 2001 Apr; 28(4):493-8. PubMed ID: 11329783
[TBL] [Abstract][Full Text] [Related]
36. A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration.
Ohtani K; Sakamoto H; Masaoka N; Shimada K; Kanaeda T; Kurihara M; Nagai N; Satoh K
Gynecol Oncol; 2000 Dec; 79(3):515-8. PubMed ID: 11104632
[TBL] [Abstract][Full Text] [Related]
37. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer.
Pickel H; Lahousen M; Petru E; Stettner H; Hackl A; Kapp K; Winter R
Gynecol Oncol; 1999 Feb; 72(2):215-9. PubMed ID: 10021304
[TBL] [Abstract][Full Text] [Related]
38. p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen.
Gadducci A; Cianci C; Cosio S; Carnino F; Fanucchi A; Buttitta F; Conte PF; Genazzani AR
Anticancer Res; 2000; 20(6C):4793-9. PubMed ID: 11205220
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel does not cause central nervous adverse effects: a prospective vigilance-controlled EEG mapping study in ovarian cancer patients.
Mayerhofer K; Bodner K; Saletu B; Bodner-Adler B; Anderer P; Hefler L; Kaider A; Leodolter S; Kainz C
Wien Klin Wochenschr; 2000 Dec; 112(23):1007-13. PubMed ID: 11190709
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study.
Ansquer Y; Leblanc E; Clough K; Morice P; Dauplat J; Mathevet P; Lhommé C; Scherer C; Tigaud JD; Benchaib M; Fourme E; Castaigne D; Querleu D; Dargent D
Cancer; 2001 Jun; 91(12):2329-34. PubMed ID: 11413522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]